Survexins and SurvexANs – novel nano-encapsulated inhibitors of Crm1-dependent nuclear export of Survivin

The inhibitor of apoptosis protein Survivin is frequently overexpressed in many cancers. Its nuclear export signal (NES) facilitates active transport into the cytoplasm, where Survivin interferes with apoptosis and thereby promotes cancer cell survival. Thus, blocking Survivin nuclear export via the nuclear export receptor Crm1/XPO1 represents a promising anticancer strategy. We identified two novel compounds, termed "Survexins," that inhibit Crm1-mediated nuclear export exhibiting distinct inhibition kinetics and reversibility. Both compounds inhibited NES-dependent nuclear export of our model biosensors including Survivin-NES biosensor and full-length Survivin in a dose-dependent manner and induced apoptosis supporting their potential as reversible therapeutic agents. To advance their clinical potential, we encapsulated the Survexins in human serum albumin-based nanoparticles (SurvexANs), leveraging the biocompatibility and high drug-loading capacity of albumin. SurvexANs were characterized and demonstrated stable morphology, controlled particle size and surface charge, and tunable drug-release properties. Importantly, encapsulation of Survexin5 preserved its inhibitory activity and kinetic properties while providing beneficial drug-release characteristics that may enable improved control of unintended cytotoxicity. These findings provide an important contribution to the exploration of nano-formulated inhibitors of CRM1-dependent nuclear export as a potential therapeutic approach for cancer therapy.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2026-11-18
DOI
https://doi.org/10.1016/j.biopha.2026.120065
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Survexins and SurvexANs – novel nano-encapsulated inhibitors of Crm1-dependent nuclear export of Survivin

Ömür Acet, Regina Bleul, Verena Fetz, Shirley K. Knauer et al.
Biomedicine & Pharmacotherapy
Nanoparticle-Based Drug Delivery
article

Survexins and SurvexANs – novel nano-encapsulated inhibitors of Crm1-dependent nuclear export of Survivin

Ömür Acet, Regina Bleul, Verena Fetz, Shirley K. Knauer, Raphael Thiermann, Mehmet Odabaşı, Roland H. Stauber, Burcu Önal Acet, Désirée Gül, Mahmoud Mirzaei
article en

Abstract

The inhibitor of apoptosis protein Survivin is frequently overexpressed in many cancers. Its nuclear export signal (NES) facilitates active transport into the cytoplasm, where Survivin interferes with apoptosis and thereby promotes cancer cell survival. Thus, blocking Survivin nuclear export via the nuclear export receptor Crm1/XPO1 represents a promising anticancer strategy. We identified two novel compounds, termed "Survexins," that inhibit Crm1-mediated nuclear export exhibiting distinct inhibition kinetics and reversibility. Both compounds inhibited NES-dependent nuclear export of our model biosensors including Survivin-NES biosensor and full-length Survivin in a dose-dependent manner and induced apoptosis supporting their potential as reversible therapeutic agents. To advance their clinical potential, we encapsulated the Survexins in human serum albumin-based nanoparticles (SurvexANs), leveraging the biocompatibility and high drug-loading capacity of albumin. SurvexANs were characterized and demonstrated stable morphology, controlled particle size and surface charge, and tunable drug-release properties. Importantly, encapsulation of Survexin5 preserved its inhibitory activity and kinetic properties while providing beneficial drug-release characteristics that may enable improved control of unintended cytotoxicity. These findings provide an important contribution to the exploration of nano-formulated inhibitors of CRM1-dependent nuclear export as a potential therapeutic approach for cancer therapy.

Biomedicine & PharmacotherapyVol. 205
Aksaray University (TR), Artvin Coruh University (TR), Johannes Gutenberg University Mainz (DE), Fraunhofer Institute for Microengineering and Microsystems (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), Tarsus University (TR), University of Duisburg-Essen (DE)
Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon